GlassScriptPhysician profile
Shamna Haris
NPI 1073899522
$10,161.30
in general payments reported to CMS, 2019-2025
39 companies · $2,207 in 2025
The $2,207 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2021: $213 · 2022: $783 · 2023: $3,898 · 2024: $2,678 · 2025: $2,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,297 · Travel and Lodging: $3,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,296.83 |
| Travel and Lodging | $3,486.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $1,374.57 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Penumbra, INC. | $1,156.94 | 2023 | Indigo System, Penumbra System |
| Bard Peripheral Vascular, INC. | $1,111.62 | 2024 | Crosser Iq, Rotarexs 6 F X 135 Cm |
| Stryker Corporation | $963.18 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Inthrill Thrombectomy Catheter |
| Boston Scientific Corporation | $875.29 | 2021-2025 | Varithena Administration Pack, Watchman Access System, General - Vascular Access |
| Medtronic, INC. | $757.06 | 2021-2025 | Abre, Venaseal, Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $454.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.49 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $335.88 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $304.51 | 2023-2025 | Eliquis, Camzyos |
| Edwards Lifesciences Corporation | $298.29 | 2021-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $227.16 | 2019-2025 | Farxiga |
| Amgen INC. | $209.89 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $193.71 | 2019-2025 | Lifevest |
| Abbott Laboratories | $165.69 | 2019-2025 | Diamondback Peripheral, Perclose Prostyle, Esprit |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $163.13 | 2023-2025 | Inspire |
| Pfizer INC. | $105.40 | 2024-2025 | |
| Biotronik INC. | $95.33 | 2023-2025 | Orsiro Mission, Trapit |
| Novo Nordisk INC | $93.92 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Cardinal Health 200 LLC | $91.80 | 2019 | |
| Alnylam Pharmaceuticals INC. | $91.65 | 2024-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $82.96 | 2023-2024 | Xarelto |
| Scpharmaceuticals INC. | $79.50 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $73.72 | 2025 | Opsumit, Uptravi, Opsynvi |
| Cardiovascular Systems INC. | $66.45 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $65.48 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $53.84 | 2024 | Arcalyst |
| Avinger INC. | $45.25 | 2023 | Pantheris |
| Kiniksa Pharmaceuticals, LTD. | $38.79 | 2023 | Arcalyst |
| Terumo Medical Corporation | $29.75 | 2022 | |
| Cardiva Medical, INC. | $29.68 | 2024 | Cardiva Vascade 6/7f Vcs |
| Bayer Healthcare Pharmaceuticals INC. | $29.59 | 2025 | |
| Cordis US Corp. | $27.84 | 2025 | Mynx Control Venous |
| Veryan Medical Incorporated | $24.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.57 | 2024 | Praluent, Evkeeza |
| Bridgebio Pharma, INC. | $19.13 | 2025 | Attruby |
| Daiichi Sankyo INC. | $18.43 | 2023 | Injectafer |
| Cook Medical LLC | $17.48 | 2019 | |
| Werfen USA LLC | $13.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamna Haris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.